Search clinical trials for: ARB (Telmisartan)

Total 4767 results

Kumamoto University
Japan Foundation for Aging and Health

Completed

A Trial of Telmisartan Prevention of Cardiovascular Disease (ATTEMPT-CVD)

Hypertension

Japan
Laboratorio Elea Phoenix S.A.
Carlos R. Rojo, MD; Facultad de Medicina, Universidad de Buenos Aires, UBA

Completed

Telmisartan for Treatment of COVID-19 Patients

COVID-19 Drug Treatment

Argentina
Universidad de Granada

Completed

Clinical Study on the Use of Symbios Xenograft for Sinus Floor Elevation

Sinus Floor Augmentation

Spain
Boehringer Ingelheim

Completed

An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination

Hypertension

Japan
Emory University
National Institute on Aging (NIA)

Completed

Health Evaluation in African Americans Using RAS Therapy (HEART)

Alzheimer's Disease

United States
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan Film-coated Tablet Compared With the Conventional Telmisartan Tablet Following Oral Administration in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Evaluation of the Effect of Telmisartan on Blood Pressure Control of High Risk Patients

Hypertension

Romania
Boehringer Ingelheim

Completed

Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension (MicCAT)

Hypertension
Boehringer Ingelheim

Completed

Natriuretic Effect of Telmisartan Versus Placebo in Patients With Mild-to-Moderate Hypertension

Hypertension
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan Film-coated Tablet Compared With Two Tablets of the Conventional Telmisartan Tablet in Healthy Male Volunteers

Healthy
IlDong Pharmaceutical Co Ltd

Completed

Compare the Pharmacokinetics of TAH(80/10/12.5) Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis (ESPRIT)

Hypertension
Boehringer Ingelheim

Withdrawn

Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice

Hypertension

Japan
Boehringer Ingelheim

Completed

INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy

Diabetic Nephropathies

Japan
Boehringer Ingelheim

Completed

Telmisartan in Mild to Moderate Hypertensive Patients

Hypertension
Boehringer Ingelheim

Completed

Pharmacokinetics of Different Formulations of Telmisartan, Amlodipine, and Hydrochlorothiazide (HCTZ) in Japanese Healthy Male Volunteers

Healthy

Japan
Yuhan Corporation

Completed

Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment

Hypertension

Korea, Republic of
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising and Multiple Oral Doses of Telmisartan / Hydrochlorothiazide (HCTZ) in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy

Hypertension

Japan
Boehringer Ingelheim

Completed

Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension

Hypertension

Japan
Boehringer Ingelheim

Completed

Relative Bioavailability of Telmisartan and HCTZ in Two Experimental Formulations Compared to the Standard Formulation Telmisartan and HCTZ in Healthy Female and Male Subjects

Healthy
Boehringer Ingelheim

Completed

Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension

Hypertension

United States, Bulgaria, Czech Republic, France, Hungary, Korea, Republic of, Romania, Russian Federation, Slovakia, Spain, Ukraine
Boehringer Ingelheim

Completed

Telmisartan Tab Hypertension

Hypertension
Boehringer Ingelheim

Completed

Micardis®. Observational Study in Patients With Essential Hypertension

Hypertension
Boehringer Ingelheim

Completed

Filtered Trial for Telmisartan 40mg Non-responder

Hypertension

Japan
Boehringer Ingelheim

Completed

Study of Hypertensive Population Under Treatment With Telmisartan in Real Clinical Conditions With the Goal to Control Early Morning Blood Pressure Rise

Hypertension

Belgium, Canada, Colombia, Czechia, Ecuador, Indonesia, Jordan, Lebanon, Mexico, Turkey, Venezuela, Yemen
University of Campania "Luigi Vanvitelli"

Completed

Telmisartan in Haemodialysis Patients With Chronic Heart Failure

Heart Failure, Congestive

Italy
Boehringer Ingelheim

Terminated

SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients

Hypertension | Coronary Arteriosclerosis

Germany
Ludwig-Maximilians - University of Munich
Bayer

Completed

Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients (METATEL)

Hypertension | Metabolic Syndrome | Hypertriglyceridemia

Germany
Boehringer Ingelheim

Completed

An Observational Study to Investigate the Efficacy, Safety, Tolerability and the Effect on Quality of Life of Telmisartan (Micardis) and Telmisartan With HCTZ (Micardis Plus) in Patients With Hypertension

Hypertension

Korea, Republic of
Boehringer Ingelheim

Completed

Safety Evaluation of Telmisartan Plus Hydrochlorothiazide in Patients With Mild-to-Moderate Hypertension

Hypertension
University of Hawaii
National Institute on Minority Health and Health Disparities (NIMHD)

Terminated

Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients

COVID-19

United States
Xiaoduo Fan

Terminated

Telmisartan Pilot Study on Treatment Resistant Schizophrenia

Schizophrenia | Schizo Affective Disorder | Treatment-resistant Schizophrenia

United States
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan as Telmisartan 80 mg/HCTZ 12.5 mg Fixed-dose Combination Tablet or as Two Telmisartan 40 mg Tablets in Healthy Male Volunteers

Healthy
George Medicines PTY Limited

Completed

Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension (GMRx2_ACT)

Hypertension

Australia, United States, United Kingdom, Poland, Sri Lanka, New Zealand, Czechia
Boehringer Ingelheim

Completed

Micardis® in Patients With Essential Hypertension

Hypertension
Bayer

Completed

COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-I Treatment Due to couGH in Poland (COUGH)

Hypertension

Poland
Medical University of Gdansk

Completed

The Effect of Various Types of the Renin-angiotensin-aldosterone System Blockade on Proteinuria

Proteinuria | Chronic Kidney Disease
Bayer
International Clinical Trials Association

Completed

Survey to Assess Why People Are Not Responding to Treatment in Hypertension

Arterial Hypertension

France
Boehringer Ingelheim
Astellas Pharma Inc

Completed

Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use

Hypertension

Japan
Boehringer Ingelheim

Completed

3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension

Hypertension

Japan
Yuhan Corporation

Completed

Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and Hyperlipidemia

Hypertension | Hyperlipidemia

Korea, Republic of
Boehringer Ingelheim

Completed

Influence of Food on the Bioavailability of Telmisartan/Amlodipine Fixed Dose Combination in Healthy Japanese Male Volunteers

Healthy
Daewon Pharmaceutical Co., Ltd.

Completed

Evaluate the Efficacy and Safety of Combination Treatment With DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients With Hypertension and Dyslipidemia

Hypertension | Dyslipidemia

Korea, Republic of
Korea University Anam Hospital

Completed

Comparison of Effects of Telmisartan and Valsartan on Neointima Volume in Diabetes

Coronary Artery Disease | Hypertension | Diabetes

Korea, Republic of
Boehringer Ingelheim

Completed

Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension

Hypertension

China
Bayer

Completed

The Real-Life Efficacy and Safety of Telmisartan in Patients With Arterial Hypertension (METABOLIC)

Hypertension

Poland, Slovakia, Croatia, Slovenia
University of Hawaii
Queens Medical Center

Terminated

INvestigating TELmisartin Study (INTEL)

Covid19

United States
Boehringer Ingelheim

Completed

Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Failed in Telmisartan 80 mg

Hypertension

China
Boehringer Ingelheim
Bayer; GlaxoSmithKline

Completed

Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose

Hypertension

United States, Canada

3

Subscribe